Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Common Equity (2020 - 2026)

Xeris Biopharma Holdings filings provide 6 years of Common Equity readings, the most recent being $13.7 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 146.22% to $13.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.7 million, a 146.22% increase, with the full-year FY2025 number at $13.7 million, up 146.22% from a year prior.
  • Common Equity hit $13.7 million in Q4 2025 for Xeris Biopharma Holdings, up from -$861000.0 in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $96.5 million in Q1 2022 to a low of -$35.1 million in Q1 2025.
  • Median Common Equity over the past 5 years was $8.8 million (2023), compared with a mean of $17.0 million.
  • Biggest five-year swings in Common Equity: surged 2336.49% in 2022 and later crashed 832.81% in 2024.
  • Xeris Biopharma Holdings' Common Equity stood at $95.2 million in 2021, then tumbled by 52.55% to $45.2 million in 2022, then plummeted by 115.01% to -$6.8 million in 2023, then plummeted by 336.67% to -$29.6 million in 2024, then skyrocketed by 146.22% to $13.7 million in 2025.
  • The last three reported values for Common Equity were $13.7 million (Q4 2025), -$861000.0 (Q3 2025), and -$19.3 million (Q2 2025) per Business Quant data.